Trial Profile

A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Sep 2024 According to a Bristol-Myers Squibb media release, data from the study were presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain (LBA43), as well as simultaneously published in The New England Journal of Medicine.
15 Sep 2024 Results presented in the Bristol-Myers Squibb Media Release
09 Sep 2024 According to a Bristol-Myers Squibb media release, Ten-year follow-up data from this study will be presented at the ESMO Congress 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com